RT Journal Article
SR Electronic
T1 CAR T-cell therapy in acute myeloid leukemia
JF Saudi Medical Journal
JO Saudi Med J
FD Prince Sultan Military Medical City
SP 1007
OP 1019
DO 10.15537/smj.2024.45.10.20240330
VO 45
IS 10
A1 Almotiri, Alhomidi
YR 2024
UL http://smj.org.sa/content/45/10/1007.abstract
AB Acute myeloid leukemia (AML) is an aggressive leukemic malignancy that affects myeloid lineage progenitors. Relapsed or refractory AML patients continue to have poor prognoses, necessitating the development of novel therapy alternatives. Adoptive T-cell therapy with chimeric antigen receptors (CARs) is an intriguing possibility in the field of leukemia treatment. Chimeric antigen receptor T-cell therapy is now being tested in clinical trials (mostly in phase I and phase II) using AML targets including CD33, CD123, and CLL-1. Preliminary data showed promising results. However, due to the cellular and molecular heterogeneity of AML and the co-expression of some AML targets on hematopoietic stem cells, these clinical investigations have shown substantial “on-target off-tumor” toxicities, indicating that more research is required. In this review, the latest significant breakthroughs in AML CAR T cell therapy are presented. Furthermore, the limitations of CAR T-cell technology and future directions to overcome these challenges are discussed.